Article
13 December 2024 - by Madeleine Cline, Justin Harris, Jian-ya Lin, Mark F. Gruenhaupt, RPh
Medicare Part D: We highlight the changes in plan incentives and key trends in 2025 formulary coverage, along with considerations for 2026.
Article
24 October 2024 - by Jake K. Klaisner, Madeleine Cline
Analyzing data from the Centers for Medicare and Medicaid Services, we highlight key changes in the prescription drug plan market for 2025.
Article
05 September 2024 - by Katherine M. Holcomb, Madeleine Cline, Jake K. Klaisner, Jennifer Carioto, Gabriela Dieguez
We explore the implications of the 2026 maximum fair prices within Medicare price negotiation, part of a paradigm shift in Part D access and cost.
Article
06 August 2024 - by Madeleine Cline, David M. Liner
We discuss key drivers behind the increased direct subsidy for Medicare Part D due to the Inflation Reduction Act, along with implications for plan sponsors.
Article
25 June 2024 - by Madeleine Cline, Michelle (Klein) Robb, Katherine M. Holcomb
We analyze the impact of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program on Part D beneficiary out-of-pocket costs.
Article
06 March 2024 - by Madeleine Cline, Jake K. Klaisner, Ali M. Heinrich, Katherine M. Holcomb, Melanie K. Kuester
How might requiring Part D coverage for anti-obesity medications affect Medicare program costs?
Article
27 November 2023 - by Madeleine Cline, Jake K. Klaisner
We review trends in the Medicare PDP market, including steady declines in the number of plans and carriers as well as the percentage of Part D members enrolled in standalone prescription drug plans.
Article
18 August 2022 - by Madeleine Cline, Jason Karcher, Jake K. Klaisner, Michelle (Klein) Robb
The Inflation Reduction Act will have countless implications for all industry stakeholders and will alter the Medicare landscape in 2023 and beyond.
Article
23 December 2021 - by Jake K. Klaisner, Madeleine Cline, Adam Barnhart
Costs rise for the federal government and members, but the impacts tend to be small given the limited utilization of plasma therapies relative to the size of the entire Medicare Part D program.
Article
09 December 2021 - by Madeleine Cline, Hans Shaw, Susan Silseth, Michelle Wang
A study of the evolution of insulin products and pricing from 2007 to 2021.